Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Tuberculosis

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 131 articles:
HTML format
Text format



Single Articles


    November 2018
  1. DEKKERS BGJ, Akkerman OW, Alffenaar JWC
    The role of therapeutic drug monitoring in treatment optimization in tuberculosis and diabetes mellitus co-morbidity.
    Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.02074.
    PubMed     Text format     Abstract available


  2. VAN RIJN SP, Zuur MA, Anthony R, Wilffert B, et al
    Evaluation of carbapenems for multi/extensive-drug resistant Mycobacterium tuberculosis treatment.
    Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.01489.
    PubMed     Text format     Abstract available


  3. ANDRES S, Groschel MI, Hillemann D, Merker M, et al
    A diagnostic algorithm to investigate pyrazinamide and ethambutol resistance in rifampicin resistant Mycobacterium tuberculosis isolates in a low incidence setting.
    Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.01798.
    PubMed     Text format     Abstract available


  4. MEIKLE V, Mossberg AK, Mitra A, Hakansson AP, et al
    A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01846.
    PubMed     Text format     Abstract available


  5. DE MIRANDA SILVA C, Hajihosseini A, Myrick J, Nole J, et al
    Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log-phase, Acid-phase and Non-Replicating-Persister (NRP)-phase in an in vitro Assay.
    Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01695.
    PubMed     Text format     Abstract available


  6. VILCHEZE C, Jacobs WR Jr
    Reply to Yew et al., "Vitamin C and Mycobacterium tuberculosis Persisters".
    Antimicrob Agents Chemother. 2018;62.
    PubMed     Text format    


  7. YEW WW, Chang KC, Leung CC, Chan DP, et al
    Vitamin C and Mycobacterium tuberculosis Persisters.
    Antimicrob Agents Chemother. 2018;62.
    PubMed     Text format    


    October 2018
  8. VAN DEN ELSEN SHJ, Sturkenboom MGG, van 't Boveneind-Vrubleuskaya N, Skrahina A, et al
    Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients.
    Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01092.
    PubMed     Text format     Abstract available


  9. MELIEF E, Bonnett SA, Zuniga ES, Parish T, et al
    Activation of 2,4-diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a putative dioxygenase.
    Antimicrob Agents Chemother. 2018 Oct 15. pii: AAC.01505.
    PubMed     Text format     Abstract available


  10. RYBNIKER J, Andreas Kohl T, Barilar I, Niemann S, et al
    No evidence for acquired mutations associated with cytochrome bc 1-inhibitor resistance in 13,559 clinical Mycobacterium tuberculosis complex isolates.
    Antimicrob Agents Chemother. 2018 Oct 15. pii: AAC.01317.
    PubMed     Text format     Abstract available


    September 2018
  11. DOAN TN, Cao P, Emeto TI, McCaw JM, et al
    Predicting the Outcomes of New Short-Course Regimens for Multi-Drug Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modelling.
    Antimicrob Agents Chemother. 2018 Sep 24. pii: AAC.01487.
    PubMed     Text format     Abstract available


  12. LOUIE A, Duncanson B, Myrick J, Maynard M, et al
    The Activity of Moxifloxacin against Acid-Phase and Non-Replicative Persister Phenotype Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
    Antimicrob Agents Chemother. 2018 Sep 24. pii: AAC.01470.
    PubMed     Text format     Abstract available


    August 2018
  13. CAO R, Teskey G, Islamoglu H, Abrahem R, et al
    Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.
    Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01132.
    PubMed     Text format     Abstract available


  14. ALFARISI O, Mave V, Gaikwad S, Sahasrabudhe T, et al
    The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment.
    Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01383.
    PubMed     Text format     Abstract available


  15. LUPIEN A, Vocat A, Foo CS, Blattes E, et al
    An optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone Macozinone (PBTZ169).
    Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.00840.
    PubMed     Text format     Abstract available


  16. KANDLER JL, Mercante AD, Dalton TL, Ezewudo MN, et al
    Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests.
    Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.00974.
    PubMed     Text format     Abstract available


  17. KOSER CU, Heyckendorf J, Andres S, Olaru ID, et al
    Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".
    Antimicrob Agents Chemother. 2018;62.
    PubMed     Text format    


  18. DOOKIE N, Naidoo K, Padayatchi N
    Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2018;62.
    PubMed     Text format    


    July 2018
  19. JAGIELSKI T, Bakula Z, Brzostek A, Minias A, et al
    Characterization of mutations conferring resistance to rifampicin in Mycobacterium tuberculosis clinical strains.
    Antimicrob Agents Chemother. 2018 Jul 30. pii: AAC.01093.
    PubMed     Text format     Abstract available


  20. PELOQUIN CA, Phillips PPJ, Mitnick CD, Eisenach K, et al
    Increased Doses Lead to Higher Drug Exposures of Levofloxacin for the Treatment of Tuberculosis.
    Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00770.
    PubMed     Text format     Abstract available


  21. PITON J, Vocat A, Lupien A, Foo C, et al
    Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00681.
    PubMed     Text format     Abstract available


  22. PIETERMAN ED, Te Brake LHM, de Knegt GJ, van der Meijden A, et al
    Assessment of the additional value of verapamil to a moxifloxacin and linezolid combination regimen in a murine tuberculosis model.
    Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.01354.
    PubMed     Text format     Abstract available


  23. AGUILAR-PEREZ C, Gracia B, Rodrigues L, Vitoria A, et al
    Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.00359.
    PubMed     Text format     Abstract available


    June 2018
  24. RANCOITA PMV, Cugnata F, Gibertoni Cruz AL, Borroni E, et al
    Validating a 14-drug microtitre plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Jun 25. pii: AAC.00344.
    PubMed     Text format     Abstract available


  25. HORITA Y, Alsultan A, Kwara A, Antwi S, et al
    Evaluation of the Adequacy of WHO revised Dosages of the First-Line Anti-Tuberculosis Drugs in Children with Tuberculosis using Population Pharmacokinetic Modeling and Simulations.
    Antimicrob Agents Chemother. 2018 Jun 18. pii: AAC.00008.
    PubMed     Text format     Abstract available


  26. DE MIRANDA SILVA C, Hajihosseini A, Myrick J, Nole J, et al
    Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log-Phase, Acid-Phase and Non-Replicating-Persister (NRP)-Phase in an In vitro Assay.
    Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00856.
    PubMed     Text format     Abstract available


  27. DRUSANO GL, Myrick J, Maynard M, Nole J, et al
    Linezolid Kills Acid Phase and Non-replicative Persister Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
    Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00221.
    PubMed     Text format     Abstract available


    May 2018
  28. ZONG Z, Jing W, Shi J, Wen S, et al
    Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China.
    Antimicrob Agents Chemother. 2018 May 29. pii: AAC.00165.
    PubMed     Text format     Abstract available


  29. SHOEN C, DeStefano M, Hafkin B, Cynamon M, et al
    In vitro and in vivo activity of contezolid (MRX-I) against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 May 21. pii: AAC.00493.
    PubMed     Text format     Abstract available


  30. AMMERMAN NC, Swanson RV, Bautista EM, Almeida DV, et al
    Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
    Antimicrob Agents Chemother. 2018 May 7. pii: AAC.00636.
    PubMed     Text format     Abstract available


  31. KAUFMANN SHE
    Indole Propionic Acid: a Small Molecule Links between Gut Microbiota and Tuberculosis.
    Antimicrob Agents Chemother. 2018;62.
    PubMed     Text format    


    April 2018
  32. SHI W, Chen J, Zhang S, Zhang W, et al
    Identification of novel mutations in LprG (rv1411c), rv0521,rv3630, rv0010c, ppsC,cyp128 associated with pyrazinoic acid/pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Apr 23. pii: AAC.00430.
    PubMed     Text format     Abstract available


  33. BOOT M, Commandeur S, Subudhi AK, Bahira M, et al
    Accelerating early anti-tuberculosis drug discovery by creating mycobacterial indicator strains that predict mode of action.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00083.
    PubMed     Text format     Abstract available


  34. ZHENG H, Williams JT, Coulson GB, Haiderer ER, et al
    HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02459.
    PubMed     Text format     Abstract available


  35. LIU Y, Pertinez H, Davies GR, Gillespie SH, et al
    Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00190.
    PubMed     Text format     Abstract available


  36. LYONS MA
    Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02359.
    PubMed     Text format     Abstract available


  37. STEFAN MA, Ugur FS, Garcia GA
    SOURCE OF THE FITNESS DEFECT IN RIFAMYCIN-RESISTANT M. TUBERCULOSIS RNA POLYMERASE AND THE MECHANISM OF COMPENSATION BY MUTATIONS IN THE beta'-SUBUNIT.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00164.
    PubMed     Text format     Abstract available


    February 2018
  38. GUPTA R, Felix CR, Akerman MP, Akerman KJ, et al
    Gold(III) macrocycles and chelates targeting Mycobacterium tuberculosis and Mycobacterium abscessus: evidence for inhibition of topoisomerase 1A.
    Antimicrob Agents Chemother. 2018 Feb 26. pii: AAC.01696.
    PubMed     Text format     Abstract available


  39. CHEN C, Gardete S, Jansen RS, Shetty A, et al
    Verapamil targets membrane energetics in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02107.
    PubMed     Text format     Abstract available


  40. HEMANTH KUMAR AK, Kumar A, Kannan T, Bhatia R, et al
    Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02410.
    PubMed     Text format     Abstract available


  41. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
    Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.01802.
    PubMed     Text format     Abstract available


  42. ZUUR MA, Ghimire S, Bolhuis MS, Wessels AMA, et al
    The Pharmacokinetics of 2000 mg Ertapenem in Tuberculosis Patients.
    Antimicrob Agents Chemother. 2018 Feb 12. pii: AAC.02250.
    PubMed     Text format     Abstract available


  43. CHEN Y, Yuan Z, Shen X, Wu J, et al
    Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.
    Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02259.
    PubMed     Text format     Abstract available


  44. SAO EMANI C, Williams MJ, Wiid I, Baker B, et al
    Compounds with potential activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02236.
    PubMed     Text format     Abstract available


    January 2018
  45. WANG Q, Pang Y, Jing W, Liu Y, et al
    Clofazimine for Treatment of Pulmonary Extensively Drug-Resistant Tuberculosis in China.
    Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02149.
    PubMed     Text format     Abstract available


  46. HUO F, Luo J, Shi J, Zong Z, et al
    Increasing Prevalence of Rifampicin-Resistant Mycobacterium tuberculosis is Associated with the Transmission of Strains Harboring Compensatory Mutations in China: A 10-year Comparative Analysis.
    Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02303.
    PubMed     Text format     Abstract available


  47. DIJKSTRA JA, van der Laan T, Akkerman OW, Bolhuis MS, et al
    In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.
    Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01724.
    PubMed     Text format     Abstract available


  48. YU X, Zeng X, Shi W, Hu Y, et al
    The validation of Cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, China.
    Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01824.
    PubMed     Text format     Abstract available


  49. VILCHEZE C, Kim J, Jacobs WR Jr
    Vitamin C potentiates the killing of Mycobacterium tuberculosis by the first-line tuberculosis drugs isoniazid and rifampicin in mice.
    Antimicrob Agents Chemother. 2018 Jan 3. pii: AAC.02165.
    PubMed     Text format     Abstract available


  50. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
    Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".
    Antimicrob Agents Chemother. 2017;62.
    PubMed     Text format    


    December 2017
  51. DOMPREH A, Tang X, Zhou J, Yang H, et al
    Effect of genetic variation of NAT2 on isoniazid, SLCO1B1, and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis.
    Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.02099.
    PubMed     Text format     Abstract available


  52. AUNG WW, Ei PW, Nyunt WW, Htwe MM, et al
    Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Myanmar.
    Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.01984.
    PubMed     Text format     Abstract available


  53. SARATHY JP, Via LE, Weiner D, Blanc L, et al
    Extreme drug tolerance of Mycobacterium tuberculosis in caseum.
    Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.02266.
    PubMed     Text format     Abstract available


  54. LEE H, Ahn S, Hwang NY, Jeon K, et al
    Limited Effect of Later-generation Fluoroquinolones in the Treatment of Ofloxacin-resistant and Moxifloxacin-susceptible Multidrug-resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.01784.
    PubMed     Text format     Abstract available


    November 2017
  55. DESHPANDE D, Srivastava S, Bendet P, Martin KR, et al
    On the antibacterial and sterilizing effect of benzylpenicillin in tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.02232.
    PubMed     Text format     Abstract available


  56. ABBADI BL, Villela AD, Rodrigues-Junior VS, Subtil FT, et al
    Revisiting activation of and the mechanism of resistance to the compound IQG-607 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 20. pii: AAC.02222.
    PubMed     Text format     Abstract available


  57. DENTI P, Garcia-Prats AJ, Draper HR, Wiesner L, et al
    Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01521.
    PubMed     Text format     Abstract available


  58. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, et al
    Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.00420.
    PubMed     Text format     Abstract available


  59. HEYCKENDORF J, Andres S, Koser CU, Olaru ID, et al
    What is resistance? Impact of phenotypic versus molecular drug resistance testing on multi- and extensively drug-resistant tuberculosis therapy.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01550.
    PubMed     Text format     Abstract available


    October 2017
  60. SUN Q, Xiao TY, Liu HC, Zhao XQ, et al
    Mutations within embCAB are associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01279.
    PubMed     Text format     Abstract available


  61. WILLBY MJ, Wijkander M, Havumaki J, Johnson K, et al
    Detection of Mycobacterium tuberculosis pncA mutations by the NIPRO GenoscholarPZA-TB II as compared to conventional sequencing.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01871.
    PubMed     Text format     Abstract available


  62. BERUBE BJ, Parish T
    Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01677.
    PubMed     Text format     Abstract available


  63. GENESTET C, Ader F, Pichat C, Lina G, et al
    Combined Antibacterial Effect of Isoniazid and Rifampicin on Four Mycobacterium tuberculosis Strains: in Vitro Experiments and Response-Surface Modeling.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01413.
    PubMed     Text format     Abstract available


  64. XU J, Tasneen R, Peloquin CA, Almeida DV, et al
    Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01692.
    PubMed     Text format     Abstract available


  65. DE WELZEN L, Eldholm V, Maharaj K, Manson AL, et al
    Whole transcriptome and genomic analysis of extensively drug-resistant Mycobacterium tuberculosis clinical isolates identifies downregulation of ethA as a mechanism of ethionamide resistance.
    Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01461.
    PubMed     Text format     Abstract available


  66. NAKATANI Y, Opel-Reading HK, Merker M, Machado D, et al
    Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance.
    Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01575.
    PubMed     Text format     Abstract available


    September 2017
  67. XU W, DeJesus MA, Rucker N, Engelhart CA, et al
    Chemical genomic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01334.
    PubMed     Text format     Abstract available


  68. KIDWAI S, Park CY, Mawatwal S, Tiwari P, et al
    The dual mechanism of action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00969.
    PubMed     Text format     Abstract available


  69. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
    Mycobacterium tuberculosis subculture results in loss of potentially clinically relevant heteroresistance.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00888.
    PubMed     Text format     Abstract available


  70. HUSZAR S, Singh V, Polcicova A, Barath P, et al
    N-Acetylglucosamine-1-phosphate transferase, WecA, as a validated drug target in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01310.
    PubMed     Text format     Abstract available


  71. PARK SW, Tasneen R, Converse PJ, Nuermberger EL, et al
    Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01502.
    PubMed     Text format     Abstract available


  72. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
    Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


  73. ARORA K, Ochoa-Montano B, Tsang PS, Blundell TL, et al
    Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


    July 2017
  74. MOOSA A, Lamprecht DA, Arora K, Barry CE 3rd, et al
    Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01338.
    PubMed     Text format     Abstract available


  75. MCNEIL MB, Dennison D, Shelton C, Parish T, et al
    In vitro isolation and characterization of oxazolidinone resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01296.
    PubMed     Text format     Abstract available


  76. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
    Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.01066.
    PubMed     Text format     Abstract available


  77. MOURIK BC, de Knegt GJ, Verbon A, Mouton JW, et al
    Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00696.
    PubMed     Text format     Abstract available


  78. PANG Y, Zong Z, Huo F, Jing W, et al
    In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00900.
    PubMed     Text format     Abstract available


  79. YANG SS, Hu YB, Wang XD, Gao YR, et al
    Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 17. pii: AAC.00551.
    PubMed     Text format     Abstract available


  80. VAN RIJN SP, Srivastava S, Wessels MA, van Soolingen D, et al
    The sterilizing effect of ertapenem-clavulanate in a hollow fiber model of tuberculosis and implications on clinical dosing.
    Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.02039.
    PubMed     Text format     Abstract available


  81. ZIMMERMAN M, Lestner J, Prideaux B, O'Brien P, et al
    Ethambutol partitioning in tuberculous pulmonary lesions explains its clinical efficacy.
    Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00924.
    PubMed     Text format     Abstract available


  82. PATEL N, O'Malley T, Zhang YK, Xia Y, et al
    A novel 6-benzyl ether benzoxaborole is active against Mycobacterium tuberculosis in vitro.
    Antimicrob Agents Chemother. 2017 Jul 3. pii: AAC.01205.
    PubMed     Text format     Abstract available


    June 2017
  83. BABLISHVILI N, Tukvadze N, Shashkina E, Mathema B, et al
    The impact of gyrB and eis mutations in improving second-line drug resistance detection among Mycobacterium tuberculosis isolates from Georgia.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.01921.
    PubMed     Text format     Abstract available


  84. LI SY, Tasneen R, Tyagi S, Soni H, et al
    Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin and pyrazinamide in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00913.
    PubMed     Text format     Abstract available


  85. RAHMAN A, Ferdous SS, Ahmed S, Rahman SMM, et al
    Pyrazinamide susceptibility and pncA mutation profile of Mycobacterium tuberculosis among multi-drug resistant tuberculosis patients in Bangladesh.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00511.
    PubMed     Text format     Abstract available


  86. CHIREHWA MT, McIlleron H, Rustomjee R, Mthiyane T, et al
    Pharmacokinetics of Pyrazinamide: optimising dosing regimens for drug-sensitive and -resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00490.
    PubMed     Text format     Abstract available


  87. RODRIGUES FELIX C, Gupta R, Geden S, Roberts J, et al
    Selective Killing Of Dormant Mycobacterium tuberculosis By Marine Natural Products.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00743.
    PubMed     Text format     Abstract available


  88. ZHANG Y, Zhang J, Cui P, Zhang W, et al
    Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008 and Rv1667c involved in pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00940.
    PubMed     Text format     Abstract available


  89. SRIVASTAVA S, Magombedze G, Koeuth T, Sherman C, et al
    Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00751.
    PubMed     Text format     Abstract available


  90. FOFANA MO, Dowdy DW
    Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


  91. ANTHONY RM, Cynamon M, Hoffner S, Werngren J, et al
    Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


    May 2017
  92. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
    Pharmacokinetic evidence to support increased doses of rifampin for tuberculosis: results from the HIRIF trial.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00038.
    PubMed     Text format     Abstract available


  93. VAN'T BOVENEIND-VRUBLEUSKAYA N, Seuruk T, van Hateren K, van der Laan T, et al
    Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis patients.
    Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00343.
    PubMed     Text format     Abstract available


  94. SLOAN DJ, McCallum AD, Schipani A, Egan D, et al
    Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 May 1. pii: AAC.00210.
    PubMed     Text format     Abstract available


  95. MOREIRA W, Santhanakrishnan S, Ngan GJY, Low CB, et al
    Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available


    April 2017
  96. NJIRE M, Wang N, Wang B, Tan Y, et al
    Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00070.
    PubMed     Text format     Abstract available


  97. VISWANATHAN G, Yadav S, Raghunand TR
    Identification of mycobacterial genes involved in antibiotic sensitivity - Implications in the treatment of tuberculosis with beta-lactam containing regimens.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00425.
    PubMed     Text format     Abstract available


  98. OLLIARO PL, Merle C, Mthiyane T, Bah B, et al
    Analysis of the effects on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.01834.
    PubMed     Text format     Abstract available


  99. DANELISHVILI L, Shulzhenko N, Chinison JJJ, Babrak L, et al
    Mycobacterium tuberculosis proteome response to anti-tuberculosis compounds reveals metabolic "escape" pathways that prolong bacterial survival.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00430.
    PubMed     Text format     Abstract available


  100. JANG J, Kim R, Woo M, Jeong J, et al
    Efflux attenuates the anti-bacterial activity of Q203 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02637.
    PubMed     Text format     Abstract available


  101. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.00226.
    PubMed     Text format     Abstract available


  102. CHEN X, Hashizume H, Tomishige T, Nakamura I, et al
    Delamanid Kills Dormant Mycobacteria in Vitro and in the Guinea Pig Model of Tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.02402.
    PubMed     Text format     Abstract available


  103. VAN RIJN SP, Zuur MA, van Altena R, Akkerman OW, et al
    Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available


    March 2017
  104. XU J, Wang B, Hu M, Huo F, et al
    Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00239.
    PubMed     Text format     Abstract available


  105. ALSULTAN A, Savic R, Dooley KE, Weiner M, et al
    Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02625.
    PubMed     Text format     Abstract available


  106. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
    Erratum for Velasquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


    February 2017
  107. RAMACHANDRAN G, Kumar AK, Chandrasekaran V, Kannan T, et al
    Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India.
    Antimicrob Agents Chemother. 2017 Feb 27. pii: AAC.02464.
    PubMed     Text format     Abstract available


  108. ROBERTS O, Khoo S, Owen A, Siccardi M, et al
    Interaction of Rifampicin and Darunavir/Ritonavir or Darunavir/Cobicistat In Vitro.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.01776.
    PubMed     Text format     Abstract available


  109. KAYIGIRE XA, Friedrich SO, van der Merwe L, Diacon AH, et al
    Acquisition of rifampin resistance in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02220.
    PubMed     Text format     Abstract available


  110. CHOI SR, Britigan BE, Narayanasamy P
    Ga(III) Nanoparticles Inhibit Growth of Both TB and HIV and Release of IL-6 and IL-8 in Co-Infected Macrophages.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02505.
    PubMed     Text format     Abstract available


    January 2017
  111. AJILEYE A, Alvarez N, Merker M, Walker TM, et al
    Some synonymous and non-synonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-resistance results to fluoroquinolones with the Hain GenoType MTBDRsl assays.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02169.
    PubMed     Text format     Abstract available


  112. DE JAGER V, van der Merwe L, Venter A, Donald PR, et al
    Time trends in sputum mycobacterial load and 2-day bactericidal activity of INH-containing anti-tuberculosis therapies.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02088.
    PubMed     Text format     Abstract available


  113. KUMAR P, Kaushik A, Bell D, Chauhan V, et al
    Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.02234.
    PubMed     Text format     Abstract available


  114. VAN ALTENA R, Dijkstra JA, van der Meer ME, Borjas Howard JF, et al
    Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.01400.
    PubMed     Text format     Abstract available


  115. SCHUMP MD, Fox DM, Bertozzi CR, Riley LW, et al
    Subcellular Partitioning and Intra-Macrophage Selectivity of Antimicrobial Compounds Against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 4. pii: AAC.01639.
    PubMed     Text format     Abstract available


    December 2016
  116. IACOBINO A, Piccaro G, Giannoni F, Mustazzolu A, et al
    Mycobacterium tuberculosis is selectively killed by rifampin and rifapentine in hypoxia at neutral pH.
    Antimicrob Agents Chemother. 2016 Dec 19. pii: AAC.02296.
    PubMed     Text format     Abstract available


  117. FOFANA MO, Shrestha S, Knight GM, Cohen T, et al
    Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.00498.
    PubMed     Text format     Abstract available


  118. PANG Y, Zhang Z, Wang Y, Wang S, et al
    Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000-2010: findings from the national survey data.
    Antimicrob Agents Chemother. 2016 Dec 5. pii: AAC.02170.
    PubMed     Text format     Abstract available


    November 2016
  119. BROSSIER F, Pham A, Bernard C, Aubry A, et al
    Molecular investigation of resistance to second line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01299.
    PubMed     Text format     Abstract available


  120. SEBASTIAN J, Swaminath S, Nair RR, Jakkala K, et al
    De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells formed against Antituberculosis Drugs In Vitro.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01343.
    PubMed     Text format     Abstract available


  121. YEE M, Gopal P, Dick T
    Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.02342.
    PubMed     Text format     Abstract available


  122. ROSEN BC, Dillon NA, Peterson ND, Minato Y, et al
    Long-Chain Fatty Acyl-CoA Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.02130.
    PubMed     Text format     Abstract available


  123. ANTWI S, Yang H, Enimil A, Sarfo AM, et al
    Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01701.
    PubMed     Text format     Abstract available


  124. ALFFENAAR JC, Akkerman OW, van Hest R
    Statin Adjunctive Therapy for Tuberculosis Treatment.
    Antimicrob Agents Chemother. 2016;60:7004.
    PubMed     Text format    


    October 2016
  125. PHOLWAT S, Stroup S, Heysell S, Ogarkov O, et al
    Eis C-14G and C-15G mutations do not confer kanamycin resistance in M. tuberculosis.
    Antimicrob Agents Chemother. 2016 Oct 10. pii: AAC.01775.
    PubMed     Text format     Abstract available


    September 2016
  126. WANG X, Yang S, Gu J, Deng J, et al
    Mycobacterium tuberculosis arylamine N-acetyltransferase acetylates and thus inactivates para-aminosalicylic acid.
    Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.01312.
    PubMed     Text format     Abstract available


  127. LI Y, Wang Y, Zhang Z, Gao H, et al
    Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China.
    Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.00532.
    PubMed     Text format     Abstract available


  128. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
    Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in MDR-TB Patients.
    Antimicrob Agents Chemother. 2016 Sep 6. pii: AAC.00632.
    PubMed     Text format     Abstract available


    May 2016
  129. NIGHTINGALE S, Chau TT, Fisher M, Nelson M, et al
    Efavirenz and metabolites in CSF; relationship with CYP2B6 c.516G>T genotype and perturbed blood-brain barrier due to tuberculous meningitis.
    Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00280.
    PubMed     Text format     Abstract available


    January 2016
  130. BEKKER A, Schaaf HS, Draper HR, van der Laan L, et al
    The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines.
    Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02600.
    PubMed     Text format     Abstract available


    November 2015
  131. CHIREHWA MT, Rustomjee R, Mthiyane T, Onyebujoh P, et al
    Model-based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of hepatic extraction.
    Antimicrob Agents Chemother. 2015 Nov 9. pii: AAC.01830.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: